Archive
531 articles, sorted by publication time.
Vivos has received IDE approval, meaning it can launch an early human study of RadioGel in the United States; this is not marketing authorization, but it allows a therapy designed to confine radiation locally within tumors to begin being tested in clinical practice.
When capital becomes more cautious, where the money goes often says more about industry conviction than total financing volume; so far this year, oncology and immune-disease drugs remain the most concentrated areas of biotech investment.
Gene medicines are reframing lipid lowering from long-term medication into a one-time or infrequent intervention; if Scribe enters the IPO market, its fundraising story will hinge not only on platform technology, but also on whether clinical evidence can keep pace with the vast cardiovascular disease market.
As competition in bispecific antibodies heats up, VERAXA must prove not only that its BiTAC technology can generate drug candidates, but also that partnerships can carry its early pipeline into the next stage of development.
Big pharma’s contest over antibody-drug conjugates is moving deeper into earlier, more fundamental layers of drug design; Myricx’s value lies not only in its drug candidates, but in a biochemical pathway that could potentially rewrite ADC payload selection.
Massachusetts biotech companies have raised nearly $3.2 billion through public listings this year, at a pace close to the pandemic-era peak; this is not only a figure signaling a market rebound, but also a reflection of investors once again sorting which scientific stories can withstand the scrutiny of public markets.
The antibody-drug conjugate boom is drawing major pharmaceutical companies toward earlier sources of technology; with a large upfront payment to acquire UK startup Myricx, Novartis is betting not only on a group of drug candidates, but also on a design logic for delivering toxic payloads into cancer cells with greater precision.
The $6.5 billion in imports reflects not only a trade deficit, but also the increasingly strained balance in a large emerging market among active pharmaceutical ingredients, patented drugs, and domestic production capacity.
The challenges in developing drugs for neurodegenerative diseases lie not only in finding new targets, but also in making early experiments more closely reflect the real responses of human nerve cells; the new collaboration between AlzeCure and QuantumCell falls at this early stage of a long R&D chain.
The FDA’s expanded pediatric approval of Vertex’s gene therapy pushes treatment options earlier in the disease course; the real challenge will lie in whether evidence in young children, transplant-like procedures, and years of follow-up can bear this promise.
InnoCare has advanced an ADC targeting a gastrointestinal tumor-related marker into human testing; this is an early step in the R&D chain, significant for validating the direction rather than declaring that efficacy has arrived.
AI drug discovery no longer attracts capital solely on the strength of platform stories; when a multinational pharmaceutical company writes the right to advance candidate molecules clinically into a contract, Hong Kong’s biotech market also begins facing a stricter question of evidence.